Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer

Trial Profile

Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2017

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 May 2017 Planned End Date changed from 1 Jun 2017 to 30 Sep 2018.
    • 06 May 2017 Planned primary completion date changed from 1 Jun 2017 to 30 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top